Background: Quality of life (QOL) has become an important outcome measure in the care of dementia patients. However, there have been few studies focusing on the difference in QOL between different dementias.
Methods: Two-hundred seventy-nine consecutive outpatients with Alzheimer's disease (AD), dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD) were recruited. The QOL was evaluated objectively using the QOL Questionnaire for Dementia (QOL-D).The QOL-D comprises six domains: positive affect, negative affect and actions, communication, restlessness, attachment to others, and spontaneity. General cognition, daily activities, and behavioral and psychological symptoms of dementia were also evaluated.
Results: The scores of positive affect of QOL-D of AD patients were significantly higher than those of patients with DLB or FTD (AD 3.1 ± 0.8, DLB 2.6 ± 0.9, FTD 2.6 ± 0.7). The scores of negative affect and action of QOL-D of FTD patients were significantly higher than those of patients with AD or DLB (FTD 2.0 ± 0.8, AD 1.4 ± 0.5, DLB 1.5 ± 0.6). The apathy scores of FTD and DLB patients were significantly higher than those of patients with AD. The disinhibition scores of FTD patients were significantly higher than those of patients with AD or DLB.
Conclusions: The apathy of FTD and DLB patients and depression of DLB patients might affect the lower positive affect of FTD and DLB patients compared to AD patients. The disinhibition of FTD patients might affect the abundance of negative affect & actions in FTD patients compared to AD and DLB patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1041610216000491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brain 18FDG-PET pattern in cognitively impaired elderly patients with bipolar disorder.
Int J Bipolar Disord
December 2024
Université Paris Cité, UMRS 1144, INSERM, Paris, France.
Background: Patients with bipolar disorder (BD) are at increased risk of dementia. The underlying mechanisms are debated. FDG-PET elucidates glucose metabolic reductions due to altered neuronal activity in the cerebral cortex, allowing detection and identification of neurodegenerative processes.
View Article and Find Full Text PDFBehavioral variant frontotemporal dementia with pathogenic variant in presenting as dementia with Lewy body disease.
Neurocase
December 2024
Department of Neurology, The Barbara and Maurice Deane Center for Wellness and Cognitive Health, Icahn School of Medicine at Mount Sinai, New York, USA.
A 75-year-old Chinese American man presented to behavioral neurology clinic for a second opinion of dementia with Lewy body disease (DLB). The clinical manifestations met the criteria for a probable DLB diagnosis. Yet, in-depth evaluation unveiled clinical history, family history, and neuroimaging evidences that suggested a diagnosis of behavioral variant frontotemporal dementia (FTD).
View Article and Find Full Text PDFMemories and mimics: unveiling the potential of FDG-PET in guiding therapeutic approaches for neurodegenerative cognitive disorders.
Front Neurol
November 2024
Department of Neurology, Northwell, New Hyde Park, NY, United States.
Article Synopsis
- FDG-PET imaging is a crucial diagnostic tool that aids in differentiating between various neurodegenerative diseases, working alongside other imaging techniques and biomarker studies.
- A systematic review and case series showed how FDG-PET imaging helped clarify uncertain neurocognitive diagnoses in a group of 19 patients, overwhelmingly improving patient care.
- The study found that Dementia with Lewy bodies is often misidentified, highlighting the importance of accurate imaging to prevent misdiagnosis of neurodegenerative conditions.
Performance of plasma p-tau217 and NfL in an unselected memory clinic setting.
Alzheimers Dement (Amst)
November 2024
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience De Boelelaan Amsterdam The Netherlands.
Introduction: Plasma phosphorylated tau-217 (p-tau217) and neurofilament light (NfL) can differentiate between different dementias in selected cohorts. We aim to test the discrimination potential of these markers in a real-world cohort.
Methods: We measured p-tau217 (ALZpath) and NfL (Quanterix) in 415 (unselected) consecutive memory clinic patients.
Pure LATE-NC: Frequency, clinical impact, and the importance of considering APOE genotype when assessing this and other subtypes of non-Alzheimer's pathologies.
Acta Neuropathol
November 2024
Sanders-Brown Center On Aging, University of Kentucky, U. Kentucky, Rm 575 Lee Todd Bldg 789 S. Limestone Ave, Lexington, KY, 40536, USA.
Pure limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (pure LATE-NC) is a term used to describe brains with LATE-NC but lacking intermediate or severe levels of Alzheimer's disease neuropathologic changes (ADNC). Focusing on pure LATE-NC, we analyzed data from the National Alzheimer's Coordinating Center (NACC) Neuropathology Data Set, comprising clinical and pathological information aggregated from 32 NIH-funded Alzheimer's Disease Research Centers (ADRCs). After excluding subjects dying with unusual conditions, n = 1,926 autopsied subjects were included in the analyses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!